论文部分内容阅读
目的 探讨人生长激素拮抗剂 (GHA ,又称生长激素受体拮抗剂 )对糖尿病小鼠肾病的干预作用。方法 雄性C5 7BL小鼠共 39只 ,分为正常对照组、糖尿病 (DM)对照组、GHA1组、GHA2组和人生长激素 (hGH)组 ,链脲佐菌素诱发糖尿病 ,后三组分别注射GHA1、GHA2和人生长激素 (hGH)为期 11周。观察各组小鼠体重、肾脏形态和尿蛋白排泄情况。结果 DM对照组、hGH组和二种GHA组小鼠体重增长差异无显著性。hGH组肾小球面积 (4 2 89± 798) μm2 和小球内细胞数 (37.4± 5 .5 )显著高于其他各组 ,二种GHA组肾小球面积和GHA2组小球内细胞数与正常对照组差异无显著性 ,各糖尿病组系膜区PAS阳性物质沉积差异无显著性。hGH和DM组尿蛋白排泄与GHA组相比差异无显著性。结论 hGH可加重DM小鼠肾小球的肥大和小球内细胞增生 ,皮下注射GHA对预防糖尿病小鼠肾小球肥大、小球内细胞增殖及保持肾小球形态的完整性有一定作用
Objective To investigate the intervention of human growth hormone antagonist (GHA), also known as growth hormone receptor antagonist, on diabetic nephropathy. Methods A total of 39 male C5 7BL mice were divided into normal control group, diabetic control group, GHA1 group, GHA2 group and human growth hormone (hGH) group, streptozotocin-induced diabetes mellitus group, GHA1, GHA2 and human growth hormone (hGH) for 11 weeks. The body weight, kidney morphology and urinary protein excretion in each group were observed. Results There was no significant difference in weight gain between the DM control group, the hGH group and the two GHA groups. The area of glomeruli (4289 ± 798) μm2 and the number of glomeruli (37.4 ± 5.5) in hGH group were significantly higher than those in other groups. The glomerular area in GHA group and the number of glomerular cells in GHA2 group No significant difference with the normal control group, the diabetic group mesangial PAS positive substance deposition was no significant difference. There was no significant difference in urinary protein excretion between hGH and DM groups compared with GHA group. Conclusion hGH can aggravate the glomerular hypertrophy and proliferation of glomeruli in DM mice. Subcutaneous injection of GHA can prevent the glomerular hypertrophy, the proliferation of glomerular cells and the integrity of glomerular morphology in diabetic mice